Endocrine cancer progression and metastases
MATTHEW D RINGEL, EDITOR-IN-CHIEF, ENDOCRINE-RELATED CANCER | Hot topics
For this anniversary issue, we invited the Editors-in-Chief of the Society's journals to write about a topic of their choice.
The development and progression of metastases are sentinel events in endocrine cancer that have a direct impact on patient outcomes. Since 1994, Endocrine-Related Cancer has provided a central platform for reporting new knowledge in all aspects of endocrine cancer progression, ranging from mechanistic studies through translational studies and clinical trials. In the first volume of the journal, the role of transforming growth factor-β in breast cancer progression was reviewed, alongside various aspects of cancer invasion and progression in prostate cancer and other malignancies, by Mahler & Denis, and Parish.
The breadth of publications on metastatic progression published in Endocrine-Related Cancer over the past 12 months has been remarkable. In prostate cancer, Labanca et al. emphasised the role of fibroblast growth factors in the development and progression of bone metastases. Tai et al. reviewed the role of extracellular vesicles in metastasis, and highlighted their potential utility as biomarkers and therapeutic vehicles. In pheochromocytoma/paraganglioma, Bechmann et al. reported on HIF2α as a predictive biomarker in human tumours and as a functional pro-metastatic factor in vitro and in vivo.
Song et al. reported novel genetic profiles of distant metastatic thyroid cancer lesions, and Creemers et al. validated IGF2 methylation as a predictive biomarker for adrenocortical carcinoma in a multicentre study. Finally, Aydemirli et al. and Myrehaug et al. reported new treatments targeting ALK gene fusions in metastatic thyroid cancer, and everolimus and radiation therapy for metastatic neuroendocrine cancers in the liver, respectively.
High impact manuscripts, such as these, that report new mechanisms of endocrine cancer progression, identify and/or validate new biomarkers of aggressive cancer behaviour, define new therapeutic targets and report clinical trials will remain key areas of emphasis for Endocrine-Related Cancer.
Read the full articles in Endocrine-Related Cancer:
Aydemirli et al. 28 377–389
Bechmann et al. 27 625–640
Creemers et al. 27 541–550
Labanca et al. 27 R255–R265
Mahler & Denis 1 37–52
Myrehaug et al. 28 541–548
Parish 1 19–36
Song et al. 27 285–293
Tai et al. 27 R133–R144